ArticleAMB Express2022
Morchella esculenta polysaccharide attenuate obesity, inflammation and modulate gut microbiota.
Article in AMB Express, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Polysaccharides from the Cherry Peel ofFoods (Basel, Switzerland) · 2026Article
- Gut microbiome-epigenetic crosstalk in obesity and type 2 diabetes: mechanisms, evidence, and translational opportunities.Frontiers in microbiology · 2026Review
- Polysaccharide-mediated modulation of gut microbiota and lysine lactylation: implications for tumor microenvironment remodeling and cancer immunotherapy.Frontiers in immunology · 2026Review
- Bio-Active Peptides from Marine Sources: Mechanistic Insights into Immune Regulation, Microbiota Modulation, and Intestinal Barrier Protection.International journal of molecular sciences · 2025Review
- Exploring the distinctive characteristics of gut microbiota across different horse breeds and ages using metataxonomics.Frontiers in cellular and infection microbiology · 2025Article
- The development prospects of morel polysaccharides as potential food functional factors: From acquisition routes to structural characteristics, derivatives, biological activity and beyond.Current research in food science · 2025Review
- Updated Progress on Polysaccharides with Anti-Diabetic Effects through the Regulation of Gut Microbiota: Sources, Mechanisms, and Structure-Activity Relationships.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Tibetan tea reduces obesity brought on by a high-fat diet and modulates gut flora in mice.Food science & nutrition · 2023Article
- Anti-Obesity Effects of Dietary Fibers Extracted from Flaxseed Cake in Diet-Induced Obese Mice.Nutrients · 2023Article
- Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.Antioxidants (Basel, Switzerland) · 2023Review
- Cultivation, nutritional value, bioactive compounds of morels, and their health benefits: A systematic review.Frontiers in nutrition · 2023Review
- Untargeted metabolomics reveals sour jujube kernel benefiting the nutritional value and flavor ofOpen life sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Edible mushrooms have now been suggested as promising sources of biological functional ingredients and are the subject of the most recent nutrition research and novel functional foods. Polysaccharides from mushrooms exhibit impressive biological effects, notably against obesity. Obesity is a chronic metabolic disorder characterized by chronic inflammation, gut dysbiosis, and hyperpermeability of the colon. Here, we prove that mushrooms Morchella esculenta polysaccharide (MEP) effects on HFD-induced obesity, colonic inflammation, and gut microbiota dysbiosis. Our findings demonstrate MEP supplementation attenuates obesity parameters and reduces inflammation in the colon via regulation of Toll-like receptor 4 (TLR4), nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and inactivation of nuclear factor kappa B (NF-κB). Furthermore, MEP administration restores gut microbiota dysregulation by ameliorating Firmicutes to Bacteroidetes proportion as well as enhancing beneficial bacteria, like Lactobacillus, and inhibiting pathogenic bacteria like Enterococcus. MEP improves gut integrity by increasing tight junction proteins (TJs) and reducing endotoxin levels by controlling Lipopolysaccharide (LPS) in HFD-induced obese mice. These results demonstrated the therapeutic efficacy of MEP in attenuating HFD-induced obesity via regulating inflammatory cascades, ameliorating the gut microbiome, and modulating gut integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.